Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aligos Therapeutics, Inc (ALGS) Fair Value & Analysis

Healthcare · US · Market cap $33.1M

Price$5.58
Fair Value$8.88
Upside+59.3%
Quality95/100
Evidence: Low Range $5.86 – $11.11

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Aligos Therapeutics, Inc (ALGS) currently trades at $5.58, while our model-based Fair Value estimate is $8.88 — implying the stock looks roughly 59.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Aligos Therapeutics, Inc (ALGS) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $8.88 versus a price of $5.58 — about +59% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ALGS?
Our 21-model fair value for Aligos Therapeutics, Inc is $8.88 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.58.
What is the quality score of ALGS?
Aligos Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.